Literature DB >> 16133244

Vaccine strategies of meningococcal disease: results of a 10-year population-based study.

Ariane Biebl1, Gabriele Hartmann, Christian Bernhard, Elmar Bechter, Anita Luckner-Hornischer, Martin Frühwirth, Sigrid Heuberger, Felix Offner, Verena Barbieri, Burkhard Simma.   

Abstract

UNLABELLED: Invasive meningococcal disease (IMD) is an important cause of morbidity and mortality in children and adults. This study was conducted to determine a possible increase in IMD in recent years with special interest focused on serogroup C disease. From January 1st 1993 to December 31st 2002, IMD was studied in one million residents of Austria. We used active, population-based surveillance data from the Office of Public Health. A total of 126 patients with positive blood and/or cerebrospinal fluid culture or positive swabs for Neisseria meningitidis were studied. The median age of all patients was 9.5 years (range 1 month to 63 years). The average incidence of all IMD subgroups was 1.05 cases per 100,000 person years and was highest in children 0-4 years old (7.08 cases per 100,000 person years) followed by young adults aged 15 to 19 years (4.35 cases per 100,000 person years). Serogroup C IMD occurred in 1.30 cases/100,000 person years in patients aged 0 to 4 years and in 1.92 cases/100,000 person years in patients aged 15 to 19 years. Overall mortality was 11.1%. There was a significant increase (P =0.001) in IMD due to serogroup B disease within the last 10 years. In contrast, serogroup C disease did not increase during the last decade.
CONCLUSION: Currently, we do not recommend mass vaccination against serogroup C disease in Austria, but young adults aged 15 to 19 years display a high incidence of meningococcal C disease. In this age group, vaccination against serogroup C disease should be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133244     DOI: 10.1007/s00431-005-1719-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Vaccination programme for group C meningococcal infection is launched.

Authors: 
Journal:  Commun Dis Rep CDR Wkly       Date:  1999-07-23

2.  Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

Authors:  Martin C J Maiden; James M Stuart
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

3.  [Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands].

Authors:  M de Vries; J Dankert; H Ruijs; A Timen; S de Greeff; H de Melker
Journal:  Ned Tijdschr Geneeskd       Date:  2002-08-17

4.  Meningococcal disease in Dallas County, Texas: results of a six-year population-based study.

Authors:  P Pastor; F B Medley; T V Murphy
Journal:  Pediatr Infect Dis J       Date:  2000-04       Impact factor: 2.129

5.  Use of anthrax vaccine in the United States.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-12-15

Review 6.  [Meningococcal disease. new prevention strategies].

Authors:  J A Soult Rubio; M Muñoz Sáez; J D López Castilla
Journal:  An Esp Pediatr       Date:  2001-01

7.  Neisseria meningitidis carriage during an outbreak of serogroup C disease.

Authors:  David M Patrick; Sylvie Champagne; Swee-Han Goh; Gillian Arsenault; Eva Thomas; Carol Shaw; Tazim Rahim; Fatma Taha; Mark Bigham; Valerie Dubenko; Danuta Skowronski; Robert C Brunham
Journal:  Clin Infect Dis       Date:  2003-10-03       Impact factor: 9.079

8.  Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.

Authors:  N Cardeñosa; A Domínguez; A Martínez; J Alvarez; H Pañella; P Godoy; S Minguell; N Camps; J A Vázquez
Journal:  Infection       Date:  2003-12       Impact factor: 3.553

9.  Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies.

Authors:  H Jaccard Ruedin; S Ess; H P Zimmermann; T Szucs
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

10.  An outbreak of serogroup C meningococcal disease in the province of Antwerp (Belgium) in 2001-2002.

Authors:  Koen De Schrijver; Inge Maes
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

  10 in total
  2 in total

Review 1.  Vaccine-induced pathogen strain replacement: what are the mechanisms?

Authors:  Maia Martcheva; Benjamin M Bolker; Robert D Holt
Journal:  J R Soc Interface       Date:  2008-01-06       Impact factor: 4.118

2.  Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.

Authors:  Koen B Pouwels; Eelko Hak; Arie van der Ende; Hannah Christensen; Germie P J M van den Dobbelsteen; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.